Decision to list medical devices supplied by ResMed NZ Limited
29 July 2019
What we are doing
We are pleased to announce the approval of a non-exclusive listing agreement with ResMed NZ Limited (“ResMed”) for the supply of non-invasive ventilation equipment and associated consumables.
This will result in 275 of ResMed’s medical devices, that can be used for non-invasive ventilation, being listed in Part III of Section H of the Pharmaceutical Schedule from 1 September 2019.
DHBs will be able to continue to purchase other suppliers’ brands of NIV Products as the agreement is not for sole supply.
Any changes to the original proposal?
As a result of consultation an extension to the range of consumables has been included in this agreement, as well as an additional range of equipment to meet an identified patient need, and better reflect current DHB requirements.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff:
- clinical staff in a range of inpatient, outpatient and community settings where NIV Products are used
- respiratory and sleep clinic specialists and support personnel
- pulmonary rehabilitation specialists
- procurement and supply chain personnel
- users of NIV Products
Detail about this decision
The RFPs were for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
Following evaluation of ResMed’s proposal, and consultation on the provisional agreement reached with them, PHARMAC has decided to list ResMed’s range of NIV Products, in Part III of Section H of the Pharmaceutical Schedule from 1 September 2019.
NIV Products from the following range of brands are included in the ResMed agreement:
- NV AcuCare
- RPS II
DHBs that purchase this category of medical devices from ResMed must do so under the terms and conditions, and the prices included in the Agreement from the listing date. DHBs can continue to choose which NIV Products they purchase.
The Agreement includes terms and conditions for training and education to be provided by ResMed, on the appropriate use of their products, which is to be provided at times as agreed with individual DHBs.
Our response to what you told us
We appreciate the time people took to respond to this consultation.
All consultation responses received by 15 July 2019 were considered in their entirety in making the decision to approve this agreement.
A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
No technical or resource impacts anticipated for Ministry of Health.
Clinician queries regarding a range of products currently purchased from ResMed for NIV purposes in general, and a specific product required for under 13kg patients, appeared to be missing from the agreement.
Further negotiations were undertaken with ResMed to determine if inclusion of the Astral range, and the extended range of associated consumables, met with the RFP requirements and could be considered for listing in this agreement. Those that did comply have been included.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 16 August 2019